Compare Adaptive Biotechnologies Corp (ADPT) vs Aptiv PLC (APTV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Aptiv PLC — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Aptiv PLC trades at $58.36 (market cap $12.45B). The key difference: Aptiv PLC is far larger — about 3.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| ADPT | APTV | |
|---|---|---|
Market Cap | $3.33B | $12.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $76.82 |
52-Week Low | $10.24 | $52.57 |
Enterprise Value | $3.19B | $19.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
APTV trades at $58.85, down 0.07% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.71, exceeding expectations of $1.62. Revenue for 2025 reached $20.40B with a net income margin of 1.77%. Analyst consensus is strongly bullish with a $80.67 price target, though technical indicators show selling pressure with support at $58.
The outlook remains mixed: strong analyst support and solid cash flow trends contrast with narrow profit margins and bearish technicals. Key risks include margin compression and high debt levels, but institutional sentiment suggests potential upside if earnings momentum continues through Q2 results on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →
